Citations

Clear

21 citation(s) found for "Shaughnessy, John".

Suppression of TRIP13 Induces Metabolic Changes and Potentiates Ferroptosis in Multiple Myeloma
Guo, Wancheng , Xu, Hongwei , Viswanathan, Prasanth, Manzano, Mark , Zangari, Maurizio , Chesi, Marta , Tricot, Guido , Shaughnessy, John D. , Cheng, Yan , Sun, Fumou , Siegel, Eric R. , Al Hadidi, Samer , Schinke, Carolina , Bergsagel, P. Leif , Rhee, Frits van , Zhan, Fenghuang

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3309-3309

10.1182/blood-2023-187001 Get It

Introduction Despite the remarkable success of combination treatments, multiple myeloma (MM) still poses significant challenges, with a high percentage of patients experiencing relapse over time. Additional metabolic alterations are found in relapsed and refractory MM; however, their impacts have not been fully elucidated. Expression of thyroid hormone receptor interactor 13 (TRIP13) has been identified by Gene Expression Profile (GEP)-70 to correlate with poor prognosis in MM. TRIP13 is an AAA ATPase that regulates the spindle assembly checkpoint in mitosis. Based on GEP data from 34 paired baseline and relapse samples, TRIP13 continuously increased from baseline to first and to second relapse. Overexpression of TRIP13 induces bortezomib resistance. In this study, we aimed to investigate how TRIP13 might regulate MM cell metabolism and to use this information to develop a novel combination strategy to overcome MM resistance. Methods Knockout (KO) of TRIP13 in OPM2 and MM1.S cells was generated by dual gRNAs CRISPR-Cas9 editing deleting a fragment between exon 4 and exon 5. Cell growth curves and response to bortezomib were recorded in the control and TRIP13-KO cells. Metabolomics was performed to reveal cellular metabolic alterations. Seahorse analysis was used to test the mitochondrial stress and glycolysis stress. To investigate whether TRIP13 KO promotes ferroptosis, an intracellular iron-dependent cell death characterized by the accumulation of lipid peroxides, we applied C11-BODIY staining after treatment with Erastin, a ferroptosis-inducer. Expression levels of cyclooxygenase 2 (encoded by PTGS2, a hallmark of ferroptosis), cystine transporter (xCT), and intracellular glutathione peroxidase 4 (GPX4) were analyzed. In addition, the protein levels of iron metabolic molecules, including iron importer transferrin receptor protein 1 (TFRC), iron exporter ferroportin 1 (FPN1), ferritin heavy chain 1 (FTH1), and nuclear receptor coactivator 4 (NCOA4) were assessed. To study whether TRIP13 KO delays MM progression in an immune-competent MM mouse model, Vκ12653 murine MM cells were genetically modified by CRISPR-mediated TRIP13-KO and then injected into C57BL/6 mice. Mouse survival was monitored. Results The cell-doubling rate of TRIP13-KO cells was decreased by 50% compared to control cells. After 24 hours of treatment with 5 nM bortezomib, cell viability of TRIP13-KO cells decreased by 31% compared with control cells. The metabolomic studies revealed that TRIP13-KO OPM2 and MM1.S cells both had significantly decreased intracellular L-serine (FC = 0.57) but increased pyruvate (FC = 1.79), citric acid (FC = 1.76), and isocitric acid (FC = 1.64), indicating TRIP13 may regulate serine metabolism, mitochondrial function, and cellular redox balance. Seahorse analysis indicated that TRIP13-KO MM cells showed decreased glycolysis (decreased by 30%, p < 0.001) and glycolytic capacity (decreased by 33%, p < 0.001) while oxidative phosphorylation showed little change. Moreover, lipid peroxidation and PTGS2 were increased in TRIP13-KO cells after Erastin treatment, indicating that these cells were more vulnerable to ferroptosis. Mechanistically, inhibition of TRIP13 decreased GPX4, FPN1, FTH1, and increased NCOA4, while overexpression of TRIP13 showed the opposite changes, suggesting that targeting TRIP13 sensitizes MM cells to ferroptosis by impairing cellular redox balance and increasing the labile-iron pool. Lastly, TRIP13-KO significantly prolonged mouse survival in the Vκ12653 mouse model (median survival: TRIP13-KO 93 days vs. Control 60.5 days, p < 0.001). Conclusion Our study revealed that TRIP13 plays a critical role in regulating MM cell metabolism. By suppressing TRIP13, we observed increased sensitivity of MM cells to bortezomib, leading to enhanced ferroptosis-mediated cell death and prolonged mouse survival. These findings strongly suggest that targeting TRIP13 could be a promising approach in MM therapy. Moving forward, our future investigations will concentrate on unraveling the precise molecular mechanisms underlying TRIP13-mediated alterations in cell metabolism. Additionally, we plan to explore the potential synergistic effects of TRIP13 inhibition in combination with metabolic targeted treatments, such as venetoclax, to further enhance therapeutic outcomes in MM.
Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma
Yu, Tiantian , Lu, Tingxun , Visco, Carlo , Chiu, April , Tam, Wayne , Zu, Youli , Hagemeister, Frederick, Ferreri, Andrés J.M. , Krieken, Joannes H.J.M. Van, Wang, Yingjun , Au, Qingyan , Zhang, Mingzhi , Shaughnessy, John D. , Xu, Bing , Zu, Youli , Xu‐Monette, Zijun Y. , Li, Yong , Snyder, Thomas M. , Tzankov, Alexandar , Bhagat, Govind , Qian, Wenbin , Dybkær, Karen , Hsi, Eric D. , Go, Heounjeong , Ponzoni, Maurilio , Møller, Michael , Parsons, Benjamin M. , Piris, Miguel Á. , Winter, Jane N. , Kirsch, Ilan R. , Young, Ken H.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 429-429

10.1182/blood-2023-179972 Get It

Introduction: In recent years, increasing evidence suggests an important role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer immunity. In various types of solid tumors, high density of TIL-Bs and presence of mature tertiary lymphoid structures consistently correlate with better prognosis and response to immune checkpoint blockade therapies. Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive lymphoma arising from mature B cells. TIL-Bs have been identified in DLBCL based on single-cell gene-expression data in several previous studies, but their prognostic significance in DLBCL is unknown. In this study, we determined the clinical significance of TIL-B abundance and investigated the potential underlying mechanisms. Patients and Methods: This abstract includes a discovery study in which we distinguished TIL-Bs from malignant B-cells by immunoglobulin gene (IG) clonotype analysis and a validation study using flow cytometry. In the discovery study, a molecularly well-characterized DLBCL cohort assembled by the International DLBCL R-CHOP Consortium Program was analyzed. DNA samples from DLBCL patients were sequenced by high-throughput ultra-deep sequencing assays using multiplexed forward and reverse primers. Based on the IG heavy chain (IGH) sequencing results, malignant B-cell and TIL-B VDJ clonotypes were identified for 138 patients, and the frequencies and numbers of TIL-B clonotypes in individual sequence repertoires were calculated. In 79 DLBCL cases, a DJ-only sequence was predominant and no productive VDJ sequences met the criteria for diagnostic sequences. Total frequencies of productive VDJ sequences in the sequence repertoires were then used to access high and low TIL-B frequencies. TIL-B frequencies were also evaluated by IG light chain clonotypes for these 217 patients and additional 52 patients. The TIL-B frequencies were correlated with patient survival, gene-expression profiling (GEP) data GSE31312, and frequencies of DLBCL-infiltrating immune cells quantified by fluorescent multiplex immunohistochemistry (mIHC). To validate the prognostic significance of TIL-B frequencies, we assembled a validation cohort of 94 DLBCL patients treated at Duke University Medical Center. TIL-Bs in tissues were quantified by flow cytometry immunophenotyping. Ratios of TIL-Bs to abnormal B cells were assessed for prognostic effects. Results: First, we found thathigh frequencies of TIL-Bs and clonotypic diversity were associated with significantly favorable prognostic effects in 138 DLBCL patients with their malignant B-cell IGH-VDJ clonotypes identified (Figure A). The prognostic effects of TIL-Bs outweighed those of the germinal center B-cell-like/activated B-cell-like classification (Figure B). Second, patients with high frequencies of TIL-Bs compared with those without had significant upregulation of immune response genes by GEP (Figure C), higher CD4 T cell infiltration quantified by fluorescent mIHC (Figure D), and enrichment of EcoTyper-defined specific cell states, including significantly increased frequencies of B cell state S2 (pre-memory), CD4 T cell state S3 (naïve), follicular helper T cell state S3, and endothelial cell state S3, whereas lower frequencies of B cell state S5 (plasmablast) and follicular helper T cell state S1. Third, high TIL-B abundance in 79 ‘DJ-only’ clonotype cases and additional 52 cases assessed by light chain clonotype analysis showed similar favorable prognostic effects and associations with upregulated immune gene expression and CD4 T cell infiltration. Fourth, the identified GEP signatures, prominent with genes involved in T-dependent B cell activation and T cell activation and differentiation, showed significant prognostic effects in two GEO datasets. Fifth, TIL-B abundance showed significant prognostic effects in DLBCL cases infiltrated with T-cells in both the discovery study (Figure E) and validation study (Figure F, flow cytometry cohort). Conclusions: TIL-B frequencies and clonotypic diversity have remarkable prognostic and biological effects in DLBCL, which has significant implications for developing novel therapeutic strategies. Our study identified a new prognostic biomarker in DLBCL and an important player in anti-lymphoma immune responses, providing a new point of view to analyze the tumor biology in aggressive B-cell lymphoma and precisely identify prognostic determinants.
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Xu‐Monette, Zijun Y. , Li, Yong , Snyder, Thomas M. , Yu, Tiantian , Lu, Tingxun , Tzankov, Alexandar , Visco, Carlo , Bhagat, Govind , Qian, Wenbin , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , Hagemeister, Fredrick B., Wang, Yingjun , Ferreri, Andrés J.M. , Møller, Michael , Parsons, Benjamin M. , Fan, Xiangshan , Au, Qingyan , Zhang, Mingzhi , Shaughnessy, John D. , Xu, Bing , Young, Ken H. , Snyder, Thomas , Lu, Tingxun , Hsi, Eric D , Hagemeister, Fredrick B , Wang, Yingjun , Go, Heounjeong , Ponzoni, Maurilio , Ferreri, Andrés J M , Møller, Michael Boe , Parsons, Benjamin M , Fan, Xiangshan , van Krieken, J Han , Piris, Miguel , Winter, Jane N , Au, Qingyan , Kirsch, Ilan , Zhang, Mingzhi , Shaughnessy, John , Xu, Bing , Young, Ken H , Tzankov, Alexandar , Dybkaer, Karen , Li, Yong , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Hsi, Eric D. , Go, Heounjeong , Ponzoni, Maurilio , Krieken, J. Han van , Piris, Miguel Á. , Winter, Jane N. , Kirsch, Ilan R.

Mayo Clinic

Clinical Cancer Research | September 20, 2023 | Volume: 29 | Issue: 23 | Pages: 4808-4821

10.1158/1078-0432.ccr-23-1554 | PMID 37728879 Get It

Abstract Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma (DLBCL) and determine the clinical and biological significance. Experimental Design: A total of 269 patients with de novo DLBCL from the International DLBCL R-CHOP Consortium Program were studied. Ultra-deep sequencing of the immunoglobulin genes was performed to determine B-cell clonotypes. The frequencies and numbers of TIL-B clonotypes in individual repertoires were correlated with patient survival, gene expression profiling (GEP) data, and frequencies of DLBCL-infiltrating immune cells quantified by fluorescent multiplex IHC at single-cell resolution. Results: TIL-B abundance, evaluated by frequencies of normal B-cell clonotypes in the immunoglobulin repertoires, remarkably showed positive associations with significantly better survival of patients in our sequenced cohorts. DLBCLs with high versus low TIL-B abundance displayed distinct GEP signatures, increased pre-memory B-cell state and naïve CD4 T-cell state fractions, and higher CD4+ T-cell infiltration. TIL-B frequency, as a new biomarker in DLBCL, outperformed the germinal center (GC) B-cell–like/activated B-cell–like classification and TIL-T frequency. The identified TIL-B–high GEP signature, including genes upregulated during T-dependent B-cell activation and those highly expressed in normal GC B cells and T cells, showed significant favorable prognostic effects in several external validation cohorts. Conclusions: TIL-B frequency is a significant prognostic factor in DLBCL and plays a crucial role in antitumor immune responses. This study provides novel insights into the prognostic determinants in DLBCL and TIL-B functions with important therapeutic implications.
A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow. (46.16)
Murray, Megan , Koorella, Chandana, Rozanski, Cheryl, Carlson, Louise, Shaughnessy, John D., Nair, Jayakumar R. , Rozanski, Cheryl, Bergsagel, P. Leif , Boise, Lawrence , Lee, Kelvin H.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 46.16-46.16

10.4049/jimmunol.188.supp.46.16 Get It

Abstract Dendritic cells (DC) are essential for the long term survival of plasma cells (PC) in the bone marrow and for the maintenance of persistent antibody titers. But the molecular basis for these interactions is not very clear. Both normal and malignant PC (like myeloma) express the T-cell co-stimulatory molecule CD28. Our data show that CD28 expressed on PC play a major role in CD80/CD86 (B7) mediated DC induction of growth factors such as IL-6 and immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO) as well as in antibody or DC mediated protection of PC in vitro. While IL-6 protected PC in vitro, IDO induced the formation of regulatory T cells in culture. Use of myeloma drug lenalidomide to inhibit DC-B7 expression or anti-CD28(Fab)2 fragments to block CD28-B7 interactions reduced DC ability to protect MM cells or produce IL-6/IDO. Moreover, just like in T-cell models, CD28 activation in malignant PC triggers similar molecular events such as tyrosine phosphorylation and association of p85. We believe that downstream of CD28, while PI3K/Akt governs survival, the Vav1/SLP76 pathway regulate PC proliferation and these form the molecular basis for a bi-directional molecular bridge between the PC and bone marrow microenvironment. Targeting this bridge could form the basis for future therapeutic strategies. Our data suggests a role for CD28-B7 in plasma cell survival by modulating the bone marrow microenvironment.
Dendritic cells support long term survival of plasma cells via CD28-CD80/CD86 interactions (66.11)
Carlson, Louise, Rozanski, Cheryl, Koorella, Chandana, Murray, Megan , Shaughnessy, John Jr, Chanan‐Khan, Asher , Nair, Jayakumar R. , Rozanski, Cheryl, Shaughnessy, John P., Bergsagel, P. Leif , Boise, Lawrence , Lee, Kelvin H.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 66.11-66.11

10.4049/jimmunol.186.supp.66.11 Get It

Abstract We have previously shown (AAI2009) that dendritic cells (DC) contribute to the survival of long lived plasma cells in the bone marrow, which are important to maintain persistent antibody titres. What is not clear are the molecular interactions that are involved. Both normal and malignant plasma cells(like myeloma cells) express the T-cell co-stimulatory molecule CD28, and both interact with DCs in the bone marrow microenvironment. CD28 activation on MM triggers similar molecular partners downstream as observed in T-cells. Gene expression analysis of normal and malignant plasma cells shows that CD28 expression correlates with poor prognostic subgroups that are associated with specific genetic lesions. In our data, while activation of CD28 with antibodies or DC-CD80/CD86 (B7) protects myeloma cells against cell death, the ligation of B7 on DCs induces DC production of plasma cell survival factor IL-6, and immunosuppressive factor indoleamine 2,3-dioxygenase (IDO). Use of Lenalidomide (a common myeloma drug) to inhibit DC-B7 expression or anti-CD28(Fab)2 fragments to block CD28-B7 interactions reduced DC ability to protect MM cells. Experiments with αCD28(Fab)2 or inhibitors of notch pathway suggest a cross talk that regulates IL-6 production. IDO activity in DC-MM cocultures, suppressed T-cell proliferation in MLRs while an IDO inhibitor alleviated this. Our data suggests a role for CD28-B7 in plasma cell survival by modulating the bone marrow microenvironment.
The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation
Anguiano, A., Barry, William T., Gasparetto, Cristina, Shaughnessy, John D. , Potti, A., Tuchman, Sascha Alexander , Chng, Wee Joo , Zhan, Fenghuang , Gasparetto, Cristina , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | August 25, 2020 | Volume: 27 | Issue: 15_suppl | Pages: 8521-8521

10.1200/jco.2009.27.15_suppl.8521 Get It

8521 Background: Several clinical and molecular prognostic factors (e.g, International Staging System [ISS] stage, plasma cell labeling index, genomic models) exist for multiple myeloma (MM). We hypothesized that exploiting gene signatures representative of oncogenic pathway deregulation (i.e., Ras, Myc, etc.), would improve MM prognostication and also aid with the identification of novel therapeutic targets. Methods: Using a discovery cohort (n=47) of patients with MM and corresponding gene expression data, we built upon current molecular risk-stratification and devised a Bayesian genomic (“metagene”) model for prognosis. We validated that model in an independent patient cohort (n=207). Finally, we incorporated ISS staging and clinical variables to construct a combined Clinico-Genomic Risk Stratification System. We further validated the combined model in a separate cohort (n=72), in a blinded manner. Results: Using gene signatures predictive of oncogenic pathway activation in the discovery cohort, we identified specific patterns (metagenes) of signaling pathway activation with prognostic relevance. In an independent validation cohort, this metagene-based model accurately predicted event free survival (EFS) independently of ISS (multivariate hazard ratio [HR] 3.4 for ISS stage, and 5.4 for the metagene model, p=0.002). Using multivariate risk modeling, we incorporated ISS staging and the metagene model into a Clinico-Genomic System and successfully stratified the validation cohort into three groups (low, intermediate, and high risk) with markedly different EFS (HR 4.2 for intermediate risk and 14.0 for high risk vs. the low risk cohort, p<0.0001). In an additional blinded validation, the Clinico-Genomic System again accurately predicted median overall survival (68.7 [low risk] vs 24.7 [intermediate risk] vs 18.7 months [high risk], p<0.0001); more accurately than either ISS or other reported genomic models. Conclusions: A combined Clinico-Genomic Risk Stratification System, building on patterns of oncogenic pathway activation and ISS staging system, improves upon current prognostic models in MM and identifies novel pathway targets for future therapeutic consideration. No significant financial relationships to disclose.
Identification of Three Novel Chromosomal Translocation Partners Involving the Immunoglobulin Loci in Newly Diagnosed Myeloma and Human Myeloma Cell Lines.
Hanamura, Ichiro , Iida, Shinsuke , Ueda, Ryuzo , Cullraro, Contance, Bergsagel, Leif, Sawyer, Jeffrey R. , Barlogie, Bart , Shaughnessy, John D., Kuehl, Michael W. , Bergsagel, P. Leif

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 1552-1552

10.1182/blood.v106.11.1552.1552 Get It

Abstract Chromosomal translocations involving the immunoglobulin heavy-chain (IgH) locus at 14q32 are genetic hallmarks of human multiple myeloma (MM) and are likely primary oncogenic events in myeloma transformation. Common recurrent translocation partner genes of IgH account for 40–50% of cases and these rearrangements result in the transcriptional dysregulation of various proto-oncogenes such as CCND1, CCND3, FGFR3/MMSET, c-MAF, MAFB, MUM 1(IRF-4), c-MYC and it is becoming clear that these dysregulated genes play important roles in the pathogenesis and the treatment outcome of MM. Although the frequency of other partner genes of IgH translocations may be rare (&lt;1%), it is possible that many genes not currently identified as translocation partners are functionally converged into several signal pathways and play important roles as well. Through global gene expression profiling (GEP) studies of a large population of newly diagnosed MM, we have recently reported that dysregulation of any one of the three D-type cyclins is seen in almost all newly diagnosed MM and most patients with high levels of CCND2 expression was highly correlated with expression of c-MAF, MAFB or FGFR3/MMSET. In order to identify novel translocation partner genes in MM we combined GEP and fluorescence in situ hybridization (FISH) analysis in a large population of newly diagnsoed myeloma. We investigated whether IGH-CCND2 and IGH-MAFA translocations are seen in patients exhibiting high levels of CCND2 expression but not expressing c-MAF, MAFB, or FGFR3/MMSET. We also looked for a breakpoint and targeted gene at a non-random breakpoint at the 11q23 locus in 20 MM patients with 11q23 abnormalities detected by conventional G-banding. Here we report evidence of an IGH-CCND2 fusion in a newly diagnosed case of MM and an IGH-MAFA fusion in a newly diagnosed MM and an MGUS and also mapped the 11q23 breakpoint to within 100 kb in a newly diagnosed MM and a human myeloma cell line, NCU-MM-1 and identified an IGL Pou2AF1 fusion in the NCU-MM-1 line. Importantly these translcoatios do not involve the MLL or ATM genes. These three genes were all highly expressed as detected by GEP or quantitive RT-PCR in the samples in which these genes were translocated to IG loci. Although the frequency of these 3 translocations are very rare, they further the concept of a critical role of CCND2 expression in myelomegenesis and identifed the transcriptional coactivator Pou2AF1, which specifically associates with either OCT1 or OCT2, in the B-cell response to antigens and required for the formation of germinal centers, as a potential new translocation target in myeloma. Finally, our strategy of combining GEP signatures and cytogenetic analyses appears to be a practical means of identifying new IG- mediated translocations in myeloma.
Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).
Mitsiades, Constantine S. , Bryant, Barb, Zhan, Feng , Cheng, Wenli , Burrington, B., Richardson, Paul G. , Trepicchio, William L. , Shaughnessy, John D., Bergsagel, Leif, Damokosh, Andrew I., Boral, Anthony, Esseltine, Dixie, Schenkein, David P., Mulligan, George , Zhan, F., Eschrich, Steven A , Richardson, Paul Gerard Guy , Bergsagel, P. Leif , Anderson, Kenneth C.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3491-3491

10.1182/blood.v106.11.3491.3491 Get It

Abstract Introduction: We investigated tumor gene expression profiling (PGx) to identify predictive classifiers of response and elucidate the mechanism of efficacy of proteasome inhibition in multiple myeloma (MM) by bortezomib, a first-in-class proteasome inhibitor. Analysis of 44 samples from the SUMMIT phase 2 trial identified predictive classifiers of response in patients (pts) with refractory MM (ASH 2002, Abstr 1519). We now report on the PGx analysis of the SUMMIT-derived classifier in an independent sample set from the APEX phase 3 trial, a multicenter randomized study of 669 pts that demonstrated the superiority of bortezomib to high-dose dex for relapsed MM following 1 to 3 prior therapies (Richardson NEJM 2005). As well, we report on a new classifier of response built by combining samples from SUMMIT and MLN34101-040 (040) (a study of bortezomib in pts who failed dex in APEX or were not eligible for APEX) and tested in the APEX samples. Methods: 93 participating clinical centers collected pretreatment bone marrow aspirates and enriched tumor cells on site before centralized RNA extraction and microarray analysis. Approximately 85% of pts consented to whole-genome analysis. Quality control for RNA integrity and quantity, microarray data quality, and tumor cell purity resulted in 129 patient samples from APEX evaluable for PGx; 67 were from the bortezomib arm and 62 from the dex arm. 48 samples were evaluable from 040. Patient characteristics of this subset were similar to those of the overall study population. Predictive classifiers were identified and tested via separate training and test datasets. Results: Consistent with the SUMMIT analysis, the APEX and 040 datasets exhibit biologic features expected of MM, including the overexpression of translocation target genes such as cyclin D1, MAF, and MMSET/FGFR3. Classifiers built using only the SUMMIT samples predict the outcome of pts in the APEX bortezomib arm with an overall accuracy of 51% (sensitivity [Sn] = 49%, specificity [Sp] = 55%; P = .81) and in the dex arm with an overall accuracy of 56% (Sn = 64%, Sp = 50%; P = .31). If the classifier was built using data from both the SUMMIT and 040 trials (87 total samples), the prediction of response in the APEX bortezomib arm was statistically significant (66% accuracy, Sn = 89%, Sp = 42%; P = .006). The same classifier only predicts the response of dex-treated pts with an overall accuracy of 46% (Sn = 72%, Sp = 28%; P = .88), suggesting specificity for bortezomib. Many of the overexpressed genes associated with bortezomib insensitivity relate to protein synthesis (EIF4B, RPL5) and RNA binding (SFRS10, CPSF6). Future Directions: This work highlights practical and scientific issues that inform future efforts to implement PGx in clinical trials. Predictive accuracy may be influenced by the clinical end point, limited sample size, and/or technical considerations associated with distinct trials and genomic data. The influence of study differences (relating to pts’ time from diagnosis, number of prior therapies, molecular subtypes, or hybridization characteristics) on the ability to build classifiers and identify biologic pathways related to response are being examined; these and potential insights on drug mechanisms will be presented.
Glucocorticoid Receptor Expression Correlates with Clinical Outcome in Myeloma Patients Treated with Glucocorticoid-Containing Regimens.
Ma, Chunguang , Tessel, Michael A., Zhang, Lijun , Barlogie, Bart , Shaughnessy, John D. , Krett, Nancy , Ma, Shuo , Zhan, Fenghuang , Ma, Chunguang, Rajkumar, S. Vincent , Singhal, Seema , Rosen, Steven T.

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 1700-1700

10.1182/blood.v112.11.1700.1700 Get It

Abstract Glucocorticoid (GC) is an effective anti-myeloma agent by directly inducing apoptosis and growth inhibition in myeloma cells. The anti-myeloma action of GC is mediated by its intracellular receptor, the glucocorticoid receptor (GR). The response to GC is variable among myeloma patients and resistance to glucocorticoid treatment develops almost invariably. The mechanism regulating glucocorticoid-sensitivity in not well understood, although it has been hypothesized that the regulation might occur at both the receptor (GR) and post-receptor level. In MM.1 myeloma cell lines, we observed significant down-regulation of GR expression as the cells develop GC-resistance, suggesting that GR expression level is an important determinant of GC-response. Here we present evidence that GR expression level directly correlates with the clinical outcome in myeloma patients who were treated with GC-containing regimens. First, using a quantitative real-time PCR analysis, we performed a retrospective analysis of GR gene expression on bone marrow plasma cell samples from 35 patients with newly diagnosed myeloma who were then treated on the ECOG study E1A00. This is a phase 3 trial which randomized patients to dexamethasone (dex) alone vs. dex in combination with thalidomide. Pre-treatment expression levels of GR-alpha, GR-beta and GR-P splicing isoforms were measured for 35 patients, of whom, 10 had post-treatment samples available. Interestingly, a large variation of the GR expression levels was observed across the patient samples, with the GR-alpha being the predominant isoform. However, a clear correlation between GR expression and treatment response was not seen, likely due to the small sample size. To access a larger patient pool, we retrospectively analyzed the GR expression levels using the cDNA microarray data from the Arkansas group on 351 newly diagnosed myeloma patients treated with Total Therapy 2, of which dexamethasone was an essential component throughout the treatment course. Of the 351 patients, both event-free (EFS) and overall survivals (OS) were compared between 49 patients (14%) with low levels of GR expression and the rest (86%) with high levels of GR expression. Strikingly, the cases with low levels of GR expression were associated with statistically significantly worse EFS and OS compared to those with high levels of GR expression, with the 5-year EFS of 20% vs. 52% and OS of 34% vs. 68%, P &lt; 0.01. In summary, we have shown for the first time that the baseline level of glucocorticoid receptor expression in newly diagnosed myeloma patients predicts their clinical response to GC-containing regimen and the overall clinical outcome.
The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.
Johnson, David C. , Crowley, John, Shaughnessy, John D. , Sonneveld, Pieter , Durie, Brian G.M. , Ramos, Christine, Ness, Brian G. Van , Barlogie, Bart , Hoering, Antje , Haessler, Jeff, Baris, Dalsu , Katz, Michael , Goldschmidt, Hartmut , Morgan, Gareth J. , Rajkumar, S. Vincent

Mayo Clinic

Blood | October 11, 2019 | Volume: 108 | Issue: 11 | Pages: 246-246

10.1182/blood.v108.11.246.246 Get It

Abstract We have taken a genetic strategy to define the mechanisms underlying the increased risk of VTE in myeloma patient treated with thalidomide using clinical trial data derived from the MRC, ECOG, Little Rock and HOVON trial groups. Baseline VTE rates in the MRC IX study, (CTD vs CVAD; n=748 no prophylactic anticoagulation), were 14%. Rates in both arms were equal but in the thalidomide arm, thrombotic events were all DVT’s or PE’s, whereas in the CVAD arm they split equally between line related and VTE’s. In the other comparison (CTD vs MP; n=542), the VTE rate was 17%, all in the thalidomide arm. Rates were similar or higher (30%) in the other trials depending on the intensity of treatment used. We carried out a nested case control on DNA from MRC IX on 90 VTE (45 thalidomide, 45 non-thalidomide related), matched to 180 controls. SNPlex analysis for 60 SNPs in the coagulation cascade, DNA repair, thalidomide, metabolism and myeloma specific pathways, identified 7 genes which affected risk (NBS1, MTHFR, Ku80, Cyp3A5, LGAL52 and IL12B). This suggests three major pathways contribute to the risk of thalidomide related VTE, metabolism of thalidomide, tumour responsiveness and some pro-thrombotic factors. These factors differ from non-thalidomide related risk where a strong pro-inflammatory response is most relevant. We tested this hypothesis further using an expanded panel of 3,404 SNPs (BOAC panel), using the Megalle system. Statistical analysis of this data defined the top 20 thalidomide and non-thalidomide associated SNPs, which were consistent with the initial hypothesis, the results of which exclude variation in the coagulation cascade as being a significant risk factor. We explored this hypothesis further using pathway-based analysis focussing on the MTHFR, DNA repair and WNT pathways on data from the ECOG, HOVON and Little Rock data sets. The biological relevance of the SNPs and genes identified was validated by correlating the level of expression using the Affymetrix U133 CHIP with genetic variation at the DNA level. To verify the relevance of DNA repair variability to tumour response further, we correlated gene expression profiling with response and again Ku80 was identified as one of a cluster of genes defining increased risk. The data suggests that the risk of thalidomide related VTE relates to rapid tumour lysis combined with a prothrombotic tendency, whereas in line related thrombosis, risk is dependent upon a strong proinflammatory response. We are building this genetic data into a clinical risk model in order to allow us to develop a rationale for intervention strategies.